ARCHITECT Total PSA; Alinity i Total PSA (LN 6C06/07P92)
ABBOTT LABORATORIES · Decision date Feb 12, 2026
What did the FDA decide?
FDA records P910007/S067 as a supplement to PMA P910007, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Feb 12, 2026.
FDA approval order statement
change to a new supplier of a manufacturing ingredient
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Immunology
- Decision date
- Feb 12, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
Regulatory record facts
- Identifier
- P910007/S067
- Regulatory pathway
- PMA supplement
- Applicant
- ABBOTT LABORATORIES
- Product code
- MTF
- Decision code
- OK30
- Decision date
- Feb 12, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Total, prostate specific antigen (noncomplexed & complexed) for detection of prostate cancer.
- Applicant
- ABBOTT LABORATORIES
- Product code
- MTF
- FDA device class
- 3
Review the original FDA PMA listing for the original approval scope and linked supplements.
FDA decision timeline
P910007/S067 received
Application receipt date recorded by FDA.
P910007/S067 · FDA decision
30-Day Notice
P910007/S068 · Related supplement
ARCHITECT Total PSA / Alinity i Total PSA (LN 6C06/07P92)
Timeline entries are records held by MedtechLedger for P910007. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P910007
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| ABBOTT LABORATORIES | PMA supplement | Feb 23, 2026 | FDA |
Explore the linked device profile
Other records with product code MTF
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
IMMULITE Systems PSAP930027/S041 | Siemens Healthcare Diagnostics, Inc. | PMA supplement | Sep 22, 2026 | FDA |
Atellica IM Total PSA II (tPSAII)P240021/S001 | Siemens Healthcare Diagnostics, Inc. | PMA supplement | Aug 26, 2026 | FDA |
IMMULITE Systems PSAP930027/S040 | Siemens Healthcare Diagnostics, Inc. | PMA supplement | Aug 20, 2026 | FDA |
IMMULITE 2000 PSAP930027/S039 | Siemens Healthcare Diagnostics, Inc. | PMA supplement | Jul 27, 2026 | FDA |
| Roche Diagnostics Corp. | PMA supplement | Apr 29, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
ABBOTT LABORATORIES
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 100 Abbott Park Rd., Abbott Park, IL, 60064
Sources and methodology
- Original FDA record: P910007/S067
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records




